Last reviewed · How we verify
Live-attenuated varicella-zoster virus vaccine
Live-attenuated varicella-zoster virus vaccine is a Biologic drug developed by University of Toronto. It is currently FDA-approved. Also known as: shingles vaccine, chickenpox vaccine, zoster vaccine, Zostavax® (Merck).
At a glance
| Generic name | Live-attenuated varicella-zoster virus vaccine |
|---|---|
| Also known as | shingles vaccine, chickenpox vaccine, zoster vaccine, Zostavax® (Merck) |
| Sponsor | University of Toronto |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Second Dose of Varicella Vaccine in Healthy Children (PHASE3)
- SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (PHASE2)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) (PHASE4)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Live-attenuated varicella-zoster virus vaccine CI brief — competitive landscape report
- Live-attenuated varicella-zoster virus vaccine updates RSS · CI watch RSS
- University of Toronto portfolio CI
Frequently asked questions about Live-attenuated varicella-zoster virus vaccine
What is Live-attenuated varicella-zoster virus vaccine?
Live-attenuated varicella-zoster virus vaccine is a Biologic drug developed by University of Toronto.
Who makes Live-attenuated varicella-zoster virus vaccine?
Live-attenuated varicella-zoster virus vaccine is developed and marketed by University of Toronto (see full University of Toronto pipeline at /company/university-of-toronto).
Is Live-attenuated varicella-zoster virus vaccine also known as anything else?
Live-attenuated varicella-zoster virus vaccine is also known as shingles vaccine, chickenpox vaccine, zoster vaccine, Zostavax® (Merck).
What development phase is Live-attenuated varicella-zoster virus vaccine in?
Live-attenuated varicella-zoster virus vaccine is FDA-approved (marketed).
Related
- Manufacturer: University of Toronto — full pipeline
- Also known as: shingles vaccine, chickenpox vaccine, zoster vaccine, Zostavax® (Merck)
- Compare: Live-attenuated varicella-zoster virus vaccine vs similar drugs
- Pricing: Live-attenuated varicella-zoster virus vaccine cost, discount & access